

## ERBB2/Survivin/Trp53 Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0446

DESCRIPTION	
Product Name	ERBB2/Survivin/Trp53 Circular RNA for Cancer Vaccine Research
Gene Name	ERBB2/Survivin/Trp53
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	ERBB2/Survivin/Trp53
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Ionizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine

are considered to be universal tumor antigens. (NCIT\_C114285).

#### Background

Description: An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and